Method of reconstituting human lymphoid and dendritic cells
AssigneeSystemix, Inc.
InventorAnne H. M. Galy
Life of this patent
Estimating the term…
Abstract
The invention relates to methods of enriching for hematopoietic cell populations enriched in myeloid and/or lymphoid progenitor cells based on cell specific markers. The methods also provide an enriched population of prethymic lymphoid-committed progenitor population lacking long-term hematopoietic reconstitution potential. Compositions enriched for the cells and populations of cells obtained therefrom are also provided by the invention. Methods of use of the cells are also included. Methods of genetically modifying the cells are provided as are cells obtained thereby.
Claims6
A method of reconstituting the lymphoid cells of a subject comprising administering to the subject a therapeutically effective amount of an enriched population of human hematopoietic progenitor cells capable of differentiating into lymphoid cells and which do not differentiate into erythroid and myeloid cells, wherein at least 80% of the cells in the population express the markers CD34, CD45RA, CD10, but do not express CD2, CD3, CD4, CD8, CD19, CD20, CD 14, CD15, CD16, CD56 and glycophorin.
A method of reconstituting the dendritic cells of a subject comprising administering to the subject a therapeutically effective amount of an enriched population of human hematopoietic progenitor cells capable of differentiating into dendritic cells and which do not differentiate into erythroid and myeloid cells, wherein at least 80% of the cells in the population express the markers CD34, CD45RA, CD10, but do not express CD2, CD3, CD4, CD8, CD 19, CD20, CD14, CD15, CD16, CD56 and glycophorin.
Dependencies are inferred from the claim text.